Dendritic cell immunotherapy for HIV infection: from theory to reality.
Knowledge concerning the immunology of dendritic cells (DCs) accumulated over the last few decades and the development of methodologies to generate and manipulate these cells in vitro has made their therapeutic application a reality. Currently, clinical protocols for DC-based therapeutic vaccine in HIV-infected individuals show that it is a safe and promising approach. Concomitantly, important advances continue to be made in the development of methodologies to optimize DC acquisition, as well as the selection of safe, immunogenic HIV antigens and the evaluation of immune response in treated individuals.
Oshiro
Telma Miyuki
TM
Laboratório de Investigação em Dermatologia e Imunodeficiências - LIM 56, Faculdade de Medicina da Universidade de São Paulo, Instituto de Medicina Tropical - prédio II, Av. Dr. Enéas de Carvalho Aguiar, 470 - 3o andar, CEP 05403-05000, São Paulo, Brazil. telma@lim56.imt.usp.br
de Almeida
Alexandre
A
da Silva Duarte
Alberto José
AJ
D016915:AIDS Vaccines; D000818:Animals; D017951:Antigen Presentation; D002454:Cell Differentiation; D003713:Dendritic Cells; D015488:HIV Antigens / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation
D016915:AIDS Vaccines; D015488:HIV Antigens